Immutep (IMMP) Interest Expenses (2015 - 2023)

Immutep (IMMP) posted Interest Expenses of -$221.3 million for Q4 2023, down 9.51% on a QoQ basis from -$202.1 million in Q2 2023.

Immutep (IMMP) Interest Expenses (2015 - 2023) Analysis & Trends

Immutep's Interest Expenses history runs 3 years deep, the most recent figure standing at -$221.3 million for Q4 2023.

Quarterly Interest Expenses changed N/A year-over-year to -$221.3 million in Q4 2023, while the trailing twelve-month figure through Jun 2025 was -$221.3 million (up 47.73% YoY) and the FY2025 annual result came in at $23746.0, up 17.77% from the prior year.
Interest Expenses was -$221.3 million for Q4 2023 at Immutep, down from -$202.1 million in the prior quarter.
Across five years, Interest Expenses topped out at -$202.1 million in Q2 2023 and bottomed at -$221.3 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Int Expense (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-42,141.15
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	100,000.00
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	32.89 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	420.30 Mn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	28.30 Mn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	1.17 Bn
10	Immutep	569.08 Mn	569.08 Mn	-	-

Download Data